U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07495202) titled 'A Clinical Trial Evaluating the Monkeypox Recombinant Protein Vaccine' on March 13.
Brief Summary: This study is a randomized, double-blind, placebo-controlled Phase I clinical trial representing the first-in-human (FIH) investigation of the Monkeypox recombinant protein vaccine JT118. The primary objectives are to evaluate the safety, tolerability, and immunogenicity of two doses of JT118 in healthy adults and to conduct preliminary exploration of vaccination regimens.
The study will sequentially proceed from the low-dose group to the high-dose group with Subgroup 1 (participants without prior Smallpox vaccination history) and Su...